ESR1 and cancer: Among them, NCT03643510, in which cancer response is evaluated in a prospective, single arm phase II study of the combination of CDK4 and CDK6 dual inhibitor abemaciclib and selective estrogen receptor degrader fulvestrant in hormone receptor positive recurrent endometrial carcinomas.